Does INTEGRATED BIOPHARMA INC have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores INTEGRATED BIOPHARMA INC (INBP) 38.2 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 10, returns on capital 63, balance-sheet safety 73, capital discipline 8.

Is INBP stock trading below its intrinsic value?

Against a deliberately conservative owner-earnings model (9% discount rate, 0% assumed growth, capped at 4%), estimated intrinsic value is $0.33 per share versus a recent price of $0.16 — 52% below value. This is an educational estimate computed from primary SEC filings, not investment advice.

How has INBP's Moat Score changed over time?

The record logs 2 readings since Jul 17, 2026; the latest reads 38.2 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

INTEGRATED BIOPHARMA INC

INBP · Healthcare · $5.0M mkt cap · FY2025 filings · No moat ·

Doesn't clear the bar

No moat

The four filters

Pricing power10

Median gross margin 12.0% over 10y, variable.

Returns on capital63

Median ROIC 15.0%, above the 9% hurdle in 57% of years.

Balance-sheet safety73

Net debt/EBITDA n/ax, interest coverage 44x.

Capital discipline8

Owner earnings -2.7%/yr, share count growing (dilution).

Margin of safety

Above valueOn sale

52% below value

Owner earnings (normalized): $935000
Est. intrinsic value / share: $0.33
Recent price: $0.16
Discount to value: 52% below value

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

Fundamentals

There's no normalized fundamentals series for INBP yet — it appears once ingest has processed its filings.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale38.2 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — INBP has read No moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#269 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#267ESTA Establishment Labs Holdings Inc.38.4 out of 100, No moatNo moat
#268QSI QUANTUM-SI INCORPORATED38.3 out of 100, No moatNo moat
#270NDRA ENDRA Life Sciences Inc.38.1 out of 100, No moatNo moat
#271ISCO INTERNATIONAL STEM CELL CORPORATION38.0 out of 100, No moatNo moat

Compare INBP with its nearest peers →All Healthcare companies on the Index →

Common questions about INBP

Does INTEGRATED BIOPHARMA INC have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores INTEGRATED BIOPHARMA INC (INBP) 38.2 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 10, returns on capital 63, balance-sheet safety 73, capital discipline 8.
Is INBP stock trading below its intrinsic value?: Against a deliberately conservative owner-earnings model (9% discount rate, 0% assumed growth, capped at 4%), estimated intrinsic value is $0.33 per share versus a recent price of $0.16 — 52% below value. This is an educational estimate computed from primary SEC filings, not investment advice.
How has INBP's Moat Score changed over time?: The record logs 2 readings since Jul 17, 2026; the latest reads 38.2 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows INBP’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/INBP"
  width="340" height="150" style="border:0"
  title="INBP Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell INBP. See the disclaimer.